224 related articles for article (PubMed ID: 22445557)
41. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
42. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
[TBL] [Abstract][Full Text] [Related]
43. Agreement of self- and physician-collected samples for detection of high-risk human papillomavirus infections in women attending a colposcopy clinic in Thailand.
Phoolcharoen N; Kantathavorn N; Krisorakun W; Sricharunrat T; Teerayathanakul N; Taepisitpong C; Sornsamdang G; Krongthong W; Saeloo S
BMC Res Notes; 2018 Feb; 11(1):136. PubMed ID: 29458440
[TBL] [Abstract][Full Text] [Related]
44. Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease.
Babion I; De Strooper LMA; Luttmer R; Bleeker MCG; Meijer CJLM; Heideman DAM; Wilting SM; Steenbergen RDM
Epigenetics; 2019 Jun; 14(6):558-567. PubMed ID: 30955437
[TBL] [Abstract][Full Text] [Related]
45. Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
Bhatia R; Alcaniz Boada E; Bonde JH; Quint WGV; Xu L; Ejegod DM; Cuschieri K; Arbyn M
J Clin Pathol; 2023 Mar; 76(3):172-176. PubMed ID: 34782423
[TBL] [Abstract][Full Text] [Related]
46. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
Bais AG; van Kemenade FJ; Berkhof J; Verheijen RH; Snijders PJ; Voorhorst F; Babović M; van Ballegooijen M; Helmerhorst TJ; Meijer CJ
Int J Cancer; 2007 Apr; 120(7):1505-10. PubMed ID: 17205514
[TBL] [Abstract][Full Text] [Related]
47. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.
Sellors JW; Lorincz AT; Mahony JB; Mielzynska I; Lytwyn A; Roth P; Howard M; Chong S; Daya D; Chapman W; Chernesky M
CMAJ; 2000 Sep; 163(5):513-8. PubMed ID: 11006761
[TBL] [Abstract][Full Text] [Related]
48. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
Ebisch RM; de Kuyper-de Ridder GM; Bosgraaf RP; Massuger LF; IntHout J; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Bulten J; Siebers AG; Bekkers RL; Melchers WJ
Int J Cancer; 2016 Aug; 139(3):691-9. PubMed ID: 26991464
[TBL] [Abstract][Full Text] [Related]
49. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays.
Dippmann C; Schmitz M; Wunsch K; Schütze S; Beer K; Greinke C; Ikenberg H; Hoyer H; Runnebaum IB; Hansel A; Dürst M
Clin Epigenetics; 2020 Nov; 12(1):171. PubMed ID: 33176878
[TBL] [Abstract][Full Text] [Related]
50. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
51. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
52. [Value of the BioPerfectus multiplex real time HPV assay for self-collected samples cervical cancer screening].
Chen Q; Du H; Wang C; Hu QC; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):307-311. PubMed ID: 31154711
[No Abstract] [Full Text] [Related]
53. High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya.
Ting J; Mugo N; Kwatampora J; Hill C; Chitwa M; Patel S; Gakure H; Kimani J; Schoenbach VJ; Poole C; Smith JS
Sex Transm Dis; 2013 Jul; 40(7):584-9. PubMed ID: 23965776
[TBL] [Abstract][Full Text] [Related]
54. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
55. High-risk human papillomavirus detection in self-collected vaginal samples compared with healthcare worker collected cervical samples among women attending gynecology clinics at a tertiary hospital in Pretoria, South Africa.
Tiiti TA; Mashishi TL; Nkwinika VV; Benoy I; Selabe SG; Bogers J; Lebelo RL
Virol J; 2021 Sep; 18(1):192. PubMed ID: 34556128
[TBL] [Abstract][Full Text] [Related]
56. Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors.
Rodrigues LLS; Morgado MG; Sahasrabuddhe VV; De Paula VS; Oliveira NS; Chavez-Juan E; Da Silva DM; Kast WM; Nicol AF; Pilotto JH
Gynecol Oncol; 2018 Oct; 151(1):102-110. PubMed ID: 30087059
[TBL] [Abstract][Full Text] [Related]
57. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
58. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients.
Reisner SL; Deutsch MB; Peitzmeier SM; White Hughto JM; Cavanaugh TP; Pardee DJ; McLean SA; Panther LA; Gelman M; Mimiaga MJ; Potter JE
PLoS One; 2018; 13(3):e0190172. PubMed ID: 29538411
[TBL] [Abstract][Full Text] [Related]
59. Accuracy of self-collected vaginal dry swabs using the Xpert human papillomavirus assay.
Catarino R; Vassilakos P; Bilancioni A; Bougel S; Boukrid M; Meyer-Hamme U; Petignat P
PLoS One; 2017; 12(7):e0181905. PubMed ID: 28750015
[TBL] [Abstract][Full Text] [Related]
60. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.
Polman NJ; Ebisch RMF; Heideman DAM; Melchers WJG; Bekkers RLM; Molijn AC; Meijer CJLM; Quint WGV; Snijders PJF; Massuger LFAG; van Kemenade FJ; Berkhof J
Lancet Oncol; 2019 Feb; 20(2):229-238. PubMed ID: 30658933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
